AltheRx Pharmaceuticals

AltheRx Pharmaceuticals is a privately held, clinical development company focused on advancing best-in-class compounds.

AltheRx Pharmaceuticals is a privately held, clinical development company focused on advancing best-in-class compounds with high promise in large unmet markets. The Company is focused on clinical development and optimizing commercialization through partnerships. The AltheRx name is a derivative of the name of the Greek goddess of healing, Althea. The Company’s lead product, Solabegron, is a highly differentiated novel compound being investigated for OAB and IBS, conditions that affect the quality of life for more than 90 million Americans − a number that will grow significantly as the population ages. Solabegron was discovered and first developed by GlaxoSmithKline and acquired by AltheRx in March 2011. The company’s co-founders have decades of leadership experience in the pharmaceutical and biotechnology industries. AltheRx was formed in 2010.